Pathogenicity of Species of the Achromobacter Genus in Patients From Reunion Island With Cystic Fibrosis

Key facts

Sponsor

Centre Hospitalier Universitaire de la Réunion

Principal Investigator

Thomas GARRIGOS, Pharm D, PhD

CHU La Réunion

Intervention

Biological analyses(other)

Enrollment

17 enrolled

Eligibility

All sexes

Timeline

2024 – 2027

Study locations (2)

• CHU la Réunion North, Saint-Denis, Reunion
• CHU la Réunion South, Saint-Pierre, Reunion

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Congenital pulmonary airway malformation

Additional recruiting or active studies for the same condition.

• RECRUITINGEARLY PHASE1NCT07569419
  Proof of Principle Study for an Efficacy Trial of Linaclotide for Cystic Fibrosis
  University of Nottingham
• RECRUITINGNANCT06132048
  A Usability Validation of the MuCopilot Mobile Application, a Digital Tool for the Unsupervised Objective Assessment of Cystic Fibrosis
  Ad scientiam
• RECRUITINGNANCT06302985
  Atomized Inhalation ICG for Treatment of Congenital Lung Malformations
  Jiexiong Feng
• ACTIVE NOT RECRUITINGNCT07568119
  Feasibility and Acceptance of SonoHeal for Airway Clearance and Preliminary Comparison With the Standard of Care
  Cognita Labs LLC
• RECRUITINGPHASE1NCT05504837
  A Study Assessing KB407 for the Treatment of Cystic Fibrosis
  Krystal Biotech, Inc.
• RECRUITINGNANCT05701514
  The COllaborative Neonatal Network for the First CPAM Trial
  Erasmus Medical Center
• ACTIVE NOT RECRUITINGPHASE3NCT05444257
  A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
  Vertex Pharmaceuticals Incorporated
• RECRUITINGNCT02270476
  Longitudinal Observational Study on the Course of Cystic Fibrosis Lung Disease in Patients Following Newborn Screening
  Heidelberg University

See all trials for Congenital pulmonary airway malformation →